"Ranbaxy denies US FDA allegations," the company Chairman and Managing Director Malvinder Singh told reporters here.
Shares of the drug major today opened five per cent up at Rs 430 and rallied further to touch an intra-day high of Rs 446.55, registering a gain of 9.11 per cent.
Earlier this week, the US Department of Justice had filed a motion against the company in a district court of Maryland alleging fraudulent activities.
Shares of Ranbaxy, which dropped 14.01 per cent to Rs 409.25 yesterday, today surged 7.39 per cent and was later trading at Rs 439.50 on the BSE.
More From This Section
Singh also said Ranbaxy's deal with Daiichi Sankyo stands despite charges by the US FDA, stating that the Japanese firm was well aware of the happenings of Ranbaxy with regards to US FDA.
"There is no exit clause in the agreement with Daiichi Sankyo," Singh added.